Clopidogrel

Generic Name: Clopidogrel

Brand Names: Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₆ClNO_₂S

CAS Number: 113665-84-2

Unique Ingredient Identifier: A74586SNO7

Background: Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.

Clopidogrel was granted FDA approval on 17 November 1997.

Indication: 1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；

2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；

3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events

Associated Therapies: -

Clinical Trials

Clopidogrel High Dose Evaluation for the Patient With Coronary Artery Disease in Japan

Phase 4

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Clopidogrel

First Posted Date: 2010-02-17

Last Posted Date: 2016-01-11

Lead Sponsor: Takeshi Morimoto

Target Recruit Count: 106

Registration Number: NCT01069302

Locations: 🇯🇵
Division of Cardiology, Kyoto University Hospital, Kyoto, Japan

The EFFect of hIgh Dose ClopIdogrel treatmENT in Patients With Clopidogrel Resistance

Phase 3

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Clopidogrel

First Posted Date: 2009-12-15

Last Posted Date: 2009-12-15

Lead Sponsor: Bursa Postgraduate Hospital

Target Recruit Count: 192

Registration Number: NCT01032668

Locations: 🇹🇷
Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi, Bursa, Turkey

Prasugrel/Clopidogrel Maintenance Dose Washout Study

Phase 4

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Prasugrel
Drug: Clopidogrel

First Posted Date: 2009-11-17

Last Posted Date: 2021-06-28

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 56

Registration Number: NCT01014624

Locations: 🇺🇸
Scripps Clinic, La Jolla, California, United States
🇺🇸
Black Hills Clinical Research Center, Rapid City, South Dakota, United States
🇺🇸
University of Florida Health Science Center Shands Jacksonville, Jacksonville, Florida, United States

and more 1 locations

Platelet Reactivity in Stent Thrombosis Patients

Phase 4

Completed

Conditions: Coronary Artery Stent Thrombosis

Interventions: Drug: Clopidogrel

First Posted Date: 2009-11-13

Last Posted Date: 2011-08-23

Lead Sponsor: St. Antonius Hospital

Target Recruit Count: 187

Registration Number: NCT01012544

Locations: 🇳🇱
St Antonius Hospital, Nieuwegein, Utrecht, Netherlands

Studying the Efficacy of Aspirin & Clopidogrel in Healthy Subjects With Stable Coronary Artery Disease.

Phase 4

Withdrawn

Conditions: Coronary Artery Disease

Interventions: Drug: Asprin
Drug: Clopidogrel

First Posted Date: 2009-11-11

Last Posted Date: 2018-01-31

Lead Sponsor: Neil Kleiman, MD

Registration Number: NCT01011257

Locations: 🇺🇸
The Methodist Hospital, Houston, Texas, United States

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Phase 3

Terminated

Conditions: Ischemic Attack, Transient

Interventions: Drug: placebo
Drug: Clopidogrel

First Posted Date: 2009-10-07

Last Posted Date: 2018-12-04

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 4881

Registration Number: NCT00991029

Locations: 🇺🇸
Chandler Regional Medical Center, Chandler, Arizona, United States
🇺🇸
Banner University Medical Center - Tucson Campus, Tucson, Arizona, United States
🇺🇸
George Washington University Hospital, Washington, District of Columbia, United States

and more 206 locations

Clopidogrel in High-risk Patients With Acute Non-disabling Cerebrovascular Events

Phase 3

Completed

Conditions: Stroke
Transient Ischemic Attack

Interventions: Drug: Clopidogrel
Drug: Placebo of clopidogrel and Asprin

First Posted Date: 2009-09-18

Last Posted Date: 2020-07-15

Lead Sponsor: Beijing Tiantan Hospital

Target Recruit Count: 5100

Registration Number: NCT00979589

Locations: 🇨🇳
Beijing Tian Tan Hospital, Capital Medical University, Beijing, China

Efficacy Study of Combined Prasugrel and Bivalirudin Versus Clopidogrel and Heparin in Myocardial Infarction

Phase 4

Conditions: Myocardial Infarction

Interventions: Drug: Prasugrel
Drug: Clopidogrel
Drug: Bivalirudin
Drug: Heparin

First Posted Date: 2009-09-14

Last Posted Date: 2014-01-07

Lead Sponsor: Deutsches Herzzentrum Muenchen

Target Recruit Count: 548

Registration Number: NCT00976092

Locations: 🇩🇪
Deutsches Herzzentrum Muenchen, Munich, Bavaria, Germany
🇩🇪
Klinikum rechts der Isar, Technische Universitaet Muenchen, Munich, Bavaria, Germany
🇩🇪
Herzzentrum der Segeberger Kliniken, Bad Segeberg, Germany